E Fund Management Co. Ltd. Purchases 4,407 Shares of Biohaven Ltd. (NYSE:BHVN)

E Fund Management Co. Ltd. boosted its position in Biohaven Ltd. (NYSE:BHVN) by 58.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 11,883 shares of the company’s stock after purchasing an additional 4,407 shares during the period. E Fund Management Co. Ltd.’s holdings in Biohaven were worth $412,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BHVN. Canton Hathaway LLC boosted its stake in shares of Biohaven by 2.3% in the 2nd quarter. Canton Hathaway LLC now owns 21,850 shares of the company’s stock worth $758,000 after buying an additional 500 shares during the last quarter. Arizona State Retirement System boosted its position in Biohaven by 3.7% in the second quarter. Arizona State Retirement System now owns 20,575 shares of the company’s stock worth $714,000 after purchasing an additional 730 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Biohaven by 4.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,431 shares of the company’s stock valued at $605,000 after purchasing an additional 778 shares during the period. Commonwealth Equity Services LLC increased its position in shares of Biohaven by 7.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 12,188 shares of the company’s stock valued at $667,000 after purchasing an additional 830 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Biohaven by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 12,291 shares of the company’s stock worth $672,000 after purchasing an additional 967 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Insiders Place Their Bets

In related news, Director John W. Childs bought 28,400 shares of the business’s stock in a transaction on Thursday, July 18th. The stock was acquired at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the purchase, the director now directly owns 2,339,741 shares in the company, valued at $83,458,561.47. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 16.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BHVN shares. Sanford C. Bernstein started coverage on shares of Biohaven in a report on Wednesday, September 4th. They set an “outperform” rating and a $55.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $59.00 price target on shares of Biohaven in a research note on Wednesday, September 4th. Jefferies Financial Group began coverage on Biohaven in a research note on Monday. They issued a “buy” rating and a $57.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Monday, August 19th. Finally, UBS Group lowered their target price on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $54.70.

Biohaven Stock Up 1.0 %

Shares of NYSE BHVN opened at $39.40 on Thursday. Biohaven Ltd. has a 52 week low of $16.45 and a 52 week high of $62.21. The business has a 50-day simple moving average of $38.19 and a two-hundred day simple moving average of $41.20. The company has a market cap of $3.48 billion, a P/E ratio of -5.77 and a beta of 1.30.

Biohaven (NYSE:BHVN) last issued its earnings results on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing the consensus estimate of ($1.72) by ($1.92). Equities research analysts anticipate that Biohaven Ltd. will post -8.92 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.